-
91.发明授权IMMUNOGENIC T-HELPER EPITOPES FROM HUMAN TUMOUR ANTIGENS AND IMMUNOTHERAPEUTIC METHODS USING SAID EPITOPES 有权人类肿瘤抗原的免疫原性T辅助表位和它们在免疫治疗方法
公开(公告)号：EP1794190B1
公开(公告)日：2009-08-12
申请号：EP05778354.0
申请日：2005-09-09
IPC分类号： C07K14/47 , G01N33/574 , C12N15/62
CPC分类号： C07K14/4748
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
-
公开(公告)号：EP1734048B1
公开(公告)日：2008-12-17
申请号：EP06015805.2
申请日：2003-03-27
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
-
公开(公告)号：EP1734049B1
公开(公告)日：2008-12-03
申请号：EP06015806.0
申请日：2003-03-27
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
-
公开(公告)号：EP1507795B1
公开(公告)日：2008-10-08
申请号：EP03720376.7
申请日：2003-03-27
CPC分类号： C07K7/06 , A61K38/00 , A61K48/00 , A61K2039/5158 , C07K14/4748 , G01N33/505 , G01N33/56977 , G01N33/574 , Y10S530/828
摘要： The invention relates to a tumour-associated peptide containing an amino acid sequence, which is selected from the group consisting of SEQ ID No. 1 to SEQ ID No. 79 of the enclosed sequence protocol. Said peptide has the capacity to bond to a molecule of the human major histocompatibility complex (MHC) class I. The invention also relates to the use of the peptides for producing a medicament and for treating tumorous diseases. The invention further relates to a pharmaceutical composition, which comprises at least one of the peptides.
-
95.发明公开TUMOR-ASSOCIATED PEPTIDES BINDING PROMISCUOUSLY TO HUMAN LEUKOCYTE ANTIGEN (HLA) CLASS II MOLECULES 有权肿瘤相关肽AN混杂人文LEUKOZYTENANTIGEN-（HLA）II类分子结合
公开(公告)号：EP1922335A2
公开(公告)日：2008-05-21
申请号：EP06791838.3
申请日：2006-09-05
发明人： DENGJEL, Jörn
CPC分类号： C07K14/4748 , A61K38/00 , C07K14/7051
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
-
96.发明公开T-CELL EPITOPES FROM THE ONCOFETAL ANTIGEN-IMMATURE LAMININ RECEPTOR PROTEIN AND MEDICAL USES THEREOF 审中-公开T细胞表位从未成熟LAMININREZEPTORPROTEIN（ONCOFOETAL抗原）及其医药用途
公开(公告)号：EP1874810A1
公开(公告)日：2008-01-09
申请号：EP06724593.6
申请日：2006-04-26
发明人： ZEIS, Matthias
CPC分类号： C07K14/4748
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular several tumor entities including hematological malignancies. The present invention furthermore relates to tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumor immune responses. In particular, the present invention relates to two novel peptide sequences derived from HLA class I or Il molecules of human oncofoetal antigen immature laminin receptor (OFA/iLR) which can be used in vaccine compositions for eliciting anti-tumor immune responses, namely LLAARAIVAI and ALCNTDSPL.
-
97.发明公开Tumor-associated peptides binding promiscuously to human leukocyte antigen (HLA) class II molecules 有权与人类白细胞抗原（HLA）II类分子混杂结合的肿瘤相关肽
公开(公告)号：EP1806359A1
公开(公告)日：2007-07-11
申请号：EP07007915.7
申请日：2005-09-05
发明人： Dengjel, Jörn
CPC分类号： C07K14/4748 , A61K38/00 , C07K14/7051
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 49 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 具体而言，本发明涉及癌症的免疫治疗。 本发明还涉及作为刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其他肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 具体而言，本发明涉及49种新的肽序列，其衍生自可用于引发抗肿瘤免疫应答的疫苗组合物的人类肿瘤细胞系的HLA II类分子。
-
公开(公告)号：EP1714157A2
公开(公告)日：2006-10-25
申请号：EP05701245.2
申请日：2005-01-28
IPC分类号： G01N33/68
CPC分类号： G01N33/6878 , C07K7/06 , G01N33/57484 , G01N33/6842 , G01N33/6848 , G01N2333/70539 , Y10T436/24
摘要： Described is a method for identifying and quantifying of tumour-associated peptides, wherein first at least two different sources for obtaining the peptide are provided (tumourous and healthy tissue), and, separately of one another, the peptides from the different sources are chemically modified in an identical manner by using at least two different stable isotopes of the same element. Subsequently, the peptides are isolated by a chromatographic method, and the amino acid sequences of the peptides are determined, wherein the determination of the relative amount ratios of peptides having the identical sequence from different samples one to the other occurs by using a stable isotope in the chemical modification. Furthermore, the invention relates to a tumour-associated peptide having an amino acid sequence that is selected from the group consisting of SEQ-ID No. 1 to 36 from the accompanying sequence protocol, wherein the peptide has the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I. Furthermore, the invention relates to the use of the peptides for producing a medicament and for the treatment of tumourous diseases and/or adenomatous diseases. Furthermore, a pharmaceutical composition is described that comprises at least one of the peptides.
-
99.发明公开Immunogenic T-helper epitopes from human tumour antigens and immunotherapeutic methods using said epitopes 有权免疫原T-Helfer表位免疫疗法免疫治疗方法
公开(公告)号：EP1642905A1
公开(公告)日：2006-04-05
申请号：EP04023546.7
申请日：2004-10-02
IPC分类号： C07K14/47 , A61K39/00 , G01N33/574 , C12N15/62 , C12N15/00
CPC分类号： C07K14/4748
摘要： The present invention relates to immunotherapeutic methods, and molecules and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer, in particular renal cancer. The present invention furthermore relates to tumour-associated T-helper cell peptide epitopes, alone or in combination with other tumour-associated peptides, that serve as active pharmaceutical ingredients of vaccine compositions which stimulate anti-tumour immune responses. In particular, the present invention relates to 338 novel peptide sequences derived from HLA class II molecules of human tumour cell lines which can be used in vaccine compositions for eliciting anti-tumour immune responses.
摘要翻译： 本发明涉及免疫治疗方法，以及用于免疫治疗方法的分子和细胞。 特别地，本发明涉及癌症，特别是肾癌的免疫治疗。 本发明还涉及用作刺激抗肿瘤免疫应答的疫苗组合物的活性药物成分的单独或与其它肿瘤相关肽组合的肿瘤相关T辅助细胞肽表位。 特别地，本发明涉及可用于引发抗肿瘤免疫应答的疫苗组合物中的338种来自人类肿瘤细胞系HLA II类分子的新型肽序列。
-
100.发明授权PEPTID AUS ANTIGEN MUC-1 ZUR AUSLÖSUNG EINER IMMUNREAKTION GEGEN TUMORZELLEN 有权肽与抗原MUC-1，以诱导免疫应答针对肿瘤细胞的
公开(公告)号：EP1171587B1
公开(公告)日：2004-11-24
申请号：EP00926764.2
申请日：2000-03-28
发明人： KANZ, Lothar , RAMMENSEE, Hans, Georg , BRUGGER, Wolfram , STEVANOVIC, Stefan , BROSSART, Peter
CPC分类号： C07K14/4727 , A61K39/00 , A61K48/00 , A61K2039/53
摘要： The invention relates to a peptide for triggering an immune response to tumor cells. Said peptide has an optionally modified fragment of the protein that is encoded by the gene MUC-1. Said protein triggers an HLA-A2-restricted immune response.
-
-
-
-
-
-
-
-
-
搜索结果
268 条记录 (耗时 0.031 秒)
